Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial
Conclusions. Both candidate VLP vaccines were well tolerated and elicited robust immune responses by 7–10 days that persisted through day 28. The 15/50 formulation displayed the best balance of tolerability and immunogenicity.
Clinical Trials Registration. NCT02142504. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - August 23, 2016 Category: Infectious Diseases Authors: Atmar, R. L., Baehner, F., Cramer, J. P., Song, E., Borkowski, A., Mendelman, P. M., on behalf of the NOR-201 Study Group, on Behalf of the NOR-201 Study Group, Al-Ibrahim, Bernstein, Brandon, Chu, Davis, Epstein, Frey, Rosen, Treanor Tags: VIRUSES Source Type: research
Performance of Dengue Diagnostic Tests in a Single-Specimen Diagnostic Algorithm
Conclusions. The use of molecular or NS1 antigen tests to detect DENV and one to detect anti-DENV IgM in a single serum specimen collected during the first 10 days of illness accurately identified ≥90% of dengue primary and secondary cases. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - August 23, 2016 Category: Infectious Diseases Authors: Hunsperger, E. A., Munoz-Jordan, J., Beltran, M., Colon, C., Carrion, J., Vazquez, J., Acosta, L. N., Medina-Izquierdo, J. F., Horiuchi, K., Biggerstaff, B. J., Margolis, H. S. Tags: VIRUSES Source Type: research
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response
The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second d...
Source: The Journal of Infectious Diseases - August 23, 2016 Category: Infectious Diseases Authors: Durbin, A. P., Kirkpatrick, B. D., Pierce, K. K., Carmolli, M. P., Tibery, C. M., Grier, P. L., Hynes, N., Opert, K., Jarvis, A. P., Sabundayo, B. P., McElvany, B. D., Sendra, E. A., Larsson, C. J., Jo, M., Lovchik, J. M., Luke, C. J., Walsh, M. C., Frase Tags: VIRUSES Source Type: research
Opportunistic Diseases During HIV Infection--Things Aren't What They Used to Be, or Are They?
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - August 23, 2016 Category: Infectious Diseases Authors: Furrer, H. Tags: EDITORIAL COMMENTARIES Source Type: research
Reimagining the Future of the Diagnosis of Viral Infections
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - August 23, 2016 Category: Infectious Diseases Authors: Peeling, R. W., Olliaro, P. Tags: EDITORIAL COMMENTARIES Source Type: research
